Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Bortezomib in Hepatocellular Carcinoma
NCT00077441Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Started Apr 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00077441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077441.